· Regulation · Regulation Desk
RFK Jr.'s promised peptide overhaul has the wellness community expecting unrestricted access. The actual FDA docket is a narrow list of roughly twelve peptides under review for the 503A bulks list — here is what is and isn't on it.
This brief is part of the Novusyn Research news desk. We track peptide clinical readouts, regulatory actions, and pharma developments in neutral, evidence-led language for scientifically literate readers.
For related context, see the full news desk, clinical trials tracker, regulation tracker, compound directory, and guides library.